Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Naloxone hydrochloride dihydrate, Oxycodone hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for This medicine has been prescribed for you for the treatment of severe pain, which can be adequately managed only with opioid analgesics. It contains oxycodone which belongs to a class of medicines called opioids, which are 'pain relievers'. This medicine has been prescribed to you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely. Naloxone hydrochloride is added to counteract constipation. How Myloxifin relieves pain Myloxifin contains oxycodone hydrochloride and naloxone hydrochloride as active substances. Oxycodone hydrochloride is responsible for the
pain-killing effect of Myloxifin, and is a potent analgesic ("painkiller") of the opioid group. The second active substance of Myloxifin, naloxone hydrochloride, is intended to counteract constipation. Bowel dysfunction (e.g. constipation) is a typical side effect of treatment with opioid painkillers. Myloxifin is a prolonged-release tablet, which means that its active substances are released over an extended period. Their action lasts for 12 hours. These tablets are only for use in adults.
e Myloxifin Do not take Myloxifin
Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. The most serious result of opioid overdose is respiratory depression (slow and shallow breathing). This may also cause blood oxygen levels to fall, resulting in possible fainting, etc. Tell your doctor in case you have cancer associated to peritoneal metastases or beginning bowel obstruction in advanced stages of digestive and pelvic cancers. Children and adolescents The safety and benefits of Myloxifin in children and adolescents below 18 years has not been established. How to use Myloxifin correctly Diarrhoea If you experience severe diarrhoea at the start of treatment, this may be due to the effect of naloxone. It may be a sign that bowel function is returning to normal. Such diarrhoea can occur within the first 3-5 days of treatment. If diarrhoea should persist after 3-5 days, or give you cause for concern, please contact your doctor. Switching to Myloxifin If you have been using high doses of another opioid, withdrawal symptoms may occur when you initially switch to Myloxifin treatment, e.g. restlessness, bouts of sweating and muscle pain. If you experience such symptoms, you may need to be specially monitored by your doctor. Myloxifin is not suitable for withdrawal treatment. Surgery If you need to undergo surgery, please tell your doctors that you are taking Myloxifin. You may notice remnants of the prolonged‐release tablet in your stools. Do not be alarmed, as the active substances (oxycodone hydrochloride and naloxone hydrochloride) have already been released in the stomach and gut, and absorbed into your body. Incorrect use of Myloxifin These tablets are not suitable for withdrawal treatment. Myloxifin 5 mg/2.5 mg The tablet must be swallowed whole and not be divided, broken, chewed or crushed. Myloxifin 10mg/5mg, 20 mg/10 mg and 40 mg/20 mg The tablet must not be broken, chewed or crushed. Taking chewed or crushed tablets may affect the slow release properties of the tablet and lead to the absorption of a potentially lethal dose of oxycodone hydrochloride (see under "If you take more Myloxifin than you should").
Abuse Myloxifin should never be abused, particularly if you have a drug addiction. If you are addicted to substances such as heroin, morphine or methadone, severe withdrawal symptoms are likely if you abuse Myloxifin because it contains the ingredient naloxone. Pre-existing withdrawal symptoms may be made worse. Misuse You should never misuse Myloxifin prolonged-release tablets by dissolving and injecting them (e.g. into a blood vessel). In particular, they contain talc, which can cause destruction of local tissue (necrosis) and changes in lung tissue (lung granuloma). Such abuse can also have other serious consequences and may even be fatal. Doping Athletes must be aware that this medicine may cause a positive reaction to 'anti-doping' tests. The use of Myloxifin as a doping agent may become a health hazard. Other medicines and Myloxifin Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. If you take these tablets at the same time as you take other medicines, the effect of these tablets or the other medicine may be changed. Tell your doctor if you are taking:
No interactions are expected between Myloxifin and paracetamol, acetylsalicylic acid or naltrexone. Myloxifin with food and drink and alcohol Drinking alcohol whilst taking Myloxifin may make you feel more sleepy or increase the risk of serious side effects such as shallow breathing with a risk of stopping breathing, and loss of consciousness. It is recommended not to drink alcohol while you're taking Myloxifin. You should avoid drinking grapefruit juice while you are taking Myloxifin. Pregnancy and breast-feeding If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy Do not take Myloxifin if you are pregnant or think you might be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Myloxifin during pregnancy, your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Use of Myloxifin should be avoided to the extent possible during pregnancy. If used over prolonged periods during pregnancy, oxycodone hydrochloride may lead to withdrawal symptoms in newborn infants. If oxycodone hydrochloride is given during childbirth, respiratory depression (slow and shallow breathing) may occur in the newborn infant. Breast-feeding Do not take Myloxifin while you are breastfeeding as oxycodone passes into breast milk and will affect your baby. Driving and using machines Myloxifin may affect your ability to drive or operate machines. In particular, this is likely at the start of Myloxifin therapy, after a dose increase or after switching from a different medication. However, these side effects disappear once you are on a stable Myloxifin dose. Myloxifin has been associated with sleepiness and episodes of abruptly falling asleep. If you have this side effect, you must not drive or operate machinery. Talk to your doctor if these side effects occur. Ask your doctor whether you may drive or operate machines.
Myloxifin Your prescriber should have discussed with you, how long the course or tablets will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Myloxifin is a prolonged-release tablet, which means that its active substances are released over an extended period. Their action lasts for 12
hours. Do not break, chew or crush the tablets. Taking broken, chewed or crushed tablets may lead to the absorption of a potentially lethal dose of oxycodone hydrochloride (see section 3 "If you take more Myloxifin than you should"). Unless otherwise prescribed by your doctor, the usual dose is: For the treatment of pain Adults The usual starting dose is 10 mg oxycodone hydrochloride/5 mg naloxone hydrochloride as prolonged-release tablet(s) every 12 hours. Your doctor will decide how much Myloxifin you should take every day and how to divide your total daily dose into morning and evening doses. Your doctor will also decide on any necessary dose adjustments during treatment. Your dose will be adjusted according to your level of pain and individual sensitivity. You should be given the lowest dose needed for pain relief. If you have already been treated with opioids, Myloxifin treatment can be started at a higher dose. The maximum daily dose is 160 mg oxycodone hydrochloride and 80 mg naloxone hydrochloride. If you need a higher dose, your doctor may give you additional oxycodone hydrochloride without naloxone hydrochloride. However, the maximum daily dose of oxycodone hydrochloride should not exceed 400 mg. The beneficial effect of naloxone hydrochloride on bowel activity may be affected if additional oxycodone hydrochloride is given without additional naloxone hydrochloride. If you are switched from Myloxifin to another strong opioid pain medication you have to anticipate, that your bowel function will probably worsen. If you experience pain between two doses of Myloxifin, you probably may need a rapid-acting painkiller. Myloxifin is not suitable for this. In this case, please talk to your doctor. If you have the impression that the effect of Myloxifin is too strong or too weak, please talk to your doctor or pharmacist. For the treatment of pain For doses not realisable/practicable with this strength other strengths of this medicinal product are available. Elderly patients In general, no dose adjustment is necessary for elderly patients with normal kidney and/or liver function. Liver or kidney impairment If you have an impairment of your kidney function or a mild impairment of your liver function, your attending doctor will prescribe Myloxifin with special caution. If you have a moderate or severe impairment of liver function, Myloxifin must not be used (see also section 2 "Do not take Myloxifin" and "Warnings and precautions"). Use in children and adolescents below 18 years of age Myloxifin has not yet been studied in children and adolescents under 18 years of age. Its safety and effectiveness have not been proven in children and adolescents. For this reason, Myloxifin use in children and adolescents under 18 years of age is not recommended. Method of administration For oral use. Take Myloxifin every 12 hours, according to a fixed time schedule (e.g. at 8 o'clock in the morning and 8 o'clock in the evening).
Myloxifin 5 mg/2.5 mg You should take Myloxifin with sufficient liquid (1⁄2 glass of water). The tablet must be swallowed whole and not broken, chewed or crushed. The tablet may be taken with or without food. Myloxifin 10 mg/5 mg, 20 mg/10 mg and 40 mg/20 mg You should take Myloxifin with sufficient liquid (1⁄2 glass of water). The tablet can be divided into equal doses. The tablet must not be broken, chewed or crushed. The tablet may be taken with or without food. Duration of use In general, you should not take Myloxifin for any longer than you need to. If you are on long-term treatment with Myloxifin, your doctor should regularly check whether you still need Myloxifin. If you take more Myloxifin than you should If you have taken more than the prescribed dose of Myloxifin you must inform your doctor immediately. An overdose may result in:
4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them.
Important side effects to look out for, and what to do if you are affected If you are affected by any of the following important side effects, consult your nearest doctor immediately. Slow and shallow breathing (respiratory depression) is the main danger of an opioid overdose. It mostly occurs in elderly and debilitated (weak) patients. Opioids can also cause a severe drop in blood pressure in susceptible patients.
are subdivided below into three sections treatment of pain, treatment with the active substance oxycodone hydrochloride alone. The following side effects were observed in patients with pain treatment Common (may affect up to 1 in 10 people)
Drug Withdrawal When you stop taking Myloxifin, you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating. How do I know if I am addicted? If you notice any of the following signs whilst taking Myloxifin, it could be a sign that you have become addicted.
Myloxifin Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton, bottle or blister after "EXP". The expiry date refers to the last day of that month. Blister: Do not store above 25°C. Bottles: Do not store above 30 °C. Shelf life after first opening: 3 months. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Myloxifin contains The active substances are oxycodone hydrochloride and naloxone hydrochloride. Myloxifin 5 mg/2.5 mg Each prolonged-release tablet contains 5 mg of oxycodone hydrochloride (equivalent to 4.5 mg oxycodone) and 2.5 mg of naloxone hydrochloride (as 2.74 mg naloxone hydrochloride dihydrate, equivalent to 2.25 mg naloxone). Myloxifin 10 mg/5 mg Each prolonged-release tablet contains 10 mg of oxycodone hydrochloride (equivalent to 9 mg oxycodone) and 5 mg of naloxone hydrochloride (as 5.45 mg naloxone hydrochloride dihydrate, equivalent to 4.5 mg naloxone). Myloxifin 20 mg/10 mg Each prolonged-release tablet contains 20 mg of oxycodone hydrochloride (equivalent to 18 mg oxycodone) and 10 mg of naloxone hydrochloride
(as 10.9 mg naloxone hydrochloride dihydrate, equivalent to 9 mg naloxone). Myloxifin 40 mg/20 mg Each prolonged-release tablet contains 40 mg of oxycodone hydrochloride (equivalent to 36 mg oxycodone) and 20 mg of naloxone hydrochloride (as 21.8 mg naloxone hydrochloride dihydrate, equivalent to 18 mg naloxone). The other ingredients are: Tablet core Polyvinyl acetate, Povidone K30, Sodium lauryl sulphate, Silica, colloidal anhydrous, Cellulose, microcrystalline, Magnesium stearate Tablet coating Polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc. Myloxifin 10 mg/5 mg and 40 mg/20mg also contains iron oxide red (E172) What Myloxifin looks like and contents of the pack Myloxifin 5 mg/2.5 mg White, round, biconvex prolonged-release tablet with a diameter of 4.7 mm and a height of 2.9-3.9 mm. Myloxifin 10 mg/5 mg Pink, oblong, biconvex prolonged-release tablet with break scores on both sides, with a length of 10.2 mm, a width of 4.7 mm and a height of 3.0-4.0 mm. The tablet can be divided into equal doses. Myloxifin 20 mg/10 mg White, oblong, biconvex prolonged-release tablet with break scores on both sides, with a length of 11.2 mm, a width of 5.2 mm and a height of 3.3-4.3 mm. The tablet can be divided into equal doses. Myloxifin 40 mg/20 mg Pink, oblong, biconvex prolonged-release tablet with break scores on both sides, with a length of 14.2 mm, a width of 6.7 mm and a height of 3.6-4.6 mm The tablet can be divided into equal doses. Myloxifin is available in: Child-resistant blisters of 10, 14, 20, 28, 30, 50, 56, 60, 98 and 100 prolonged-released tablets or Bottles with child-resistant screw cap containing 50, 100 or 250 prolongedreleased tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Zentiva Pharma UK Limited 12 New Fetter Lane London EC4A 1JP United Kingdom Manufacturer: Develco Pharma GmbH Grienmatt 42 79650 Schopfheim Germany This leaflet was last revised in July 2024. 1065043106
Myloxifin 10 mg/5 mg prolonged-release tablets comes as tablet containing 10mg / 5mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Myloxifin 10 mg/5 mg prolonged-release tablets is naloxone hydrochloride dihydrate, oxycodone hydrochloride.
Medicines with the same active substance, strength and form include: Oxycodone hydrochloride/Naloxone hydrochloride 10 mg/5 mg prolonged-release tablets, Sofonac 10 mg/5 mg prolonged-release tablets, Targinact 10 mg/5 mg prolonged-release tablets. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Myloxifin 10 mg/5 mg prolonged-release tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Severe pain, which can be adequately managed only with opioid analgesics.
The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.
Myloxifin is indicated in adults.
Posology
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with oxycodone in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
Analgesia
The analgesic efficacy of Myloxifin is equivalent to oxycodone hydrochloride prolonged-release formulations.
The dose should be adjusted to the intensity of pain and the sensitivity of the individual patient. Unless otherwise prescribed, Myloxifin should be administered as follows:
Adults
The usual starting dose for opioid naive patients is 10 mg/5 mg of oxycodone hydrochloride/ naloxone hydrochloride at 12 hourly intervals.
Lower strengths are available to facilitate dose titration when initiating opioid therapy and for individual dose adjustment.
Patients already receiving opioids may be started on higher doses of Oxycodone/Naloxone Myloxifin depending on their previous opioid experience.
Myloxifin 5 mg/2.5 mg is intended for dose titration when initiating opioid therapy and individual dose adjustment.
The maximum daily dose of Myloxifin is 160 mg oxycodone hydrochloride and 80 mg naloxone hydrochloride. The maximum daily dose is reserved for patients who have previously been maintained on a stable daily dose and who have become in need of an increased dose. Special attention should be given to patients with compromised renal function and patients with mild hepatic impairment if an increased dose is considered. For patients requiring higher doses of Myloxifin, administration of supplemental prolonged-release oxycodone hydrochloride at the same time intervals should be considered, taking into account the maximum daily dose of 400 mg prolonged-release oxycodone hydrochloride. In the case of supplemental oxycodone hydrochloride dosing, the beneficial effect of naloxone hydrochloride on bowel function may be impaired.
After complete discontinuation of therapy with Myloxifin with a subsequent switch to another opioid a worsening of the bowel function can be expected.
Some patients taking Myloxifin according to a regular time schedule require immediate-release analgesics as “rescue” medication for breakthrough pain. Myloxifin is a prolonged-release formulation and therefore not intended for the treatment of breakthrough pain. For the treatment of breakthrough pain, a single dose of “rescue medication” should approximate one sixth of the equivalent daily dose of oxycodone hydrochloride. The need for more than two “rescues” per day is usually an indication that the dose of Myloxifin requires upward adjustment. This adjustment should be made every 1-2 days in steps of twice daily 5 mg/2.5 mg, or where necessary <2.5 mg/1.25 mg or> 10 mg/5 mg, oxycodone hydrochloride/naloxone hydrochloride until a stable dose is reached. The aim is to establish a patient-specific twice daily dose that will maintain adequate analgesia and make use of as little rescue medication as possible for as long as pain therapy is necessary. <Slightly elevated (dose corrected) peak plasma concentrations should be taken into account when the 2.5 mg/1.25 mg tablet is used.>
Myloxifin is taken at the determined dose twice daily according to a fixed time schedule. While symmetric administration (the same dose mornings and evenings) subject to a fixed time schedule (every 12 hours) is appropriate for the majority of patients, some patients, depending on the individual pain situation, may benefit from asymmetric dosing tailored to their pain pattern. In general, the lowest effective analgesic dose should be selected.
In non-malignant pain therapy, daily doses of up to 40 mg/20 mg oxycodone hydrochloride/naloxone hydrochloride are usually sufficient, but higher doses may be needed.
For doses not realisable/practicable with this strength other strengths of this medicinal product are available.
Analgesia
Paediatric population
The safety and efficacy of Myloxifin in children and adolescents aged below 18 years has not been established. No data are available.
Elderly patients
As for younger adults the dose should be adjusted to the intensity of the pain and the sensitivity of the individual patient.
Patients with impaired hepatic function
A clinical trial has shown that plasma concentrations of both oxycodone and naloxone are elevated in patients with hepatic impairment. Naloxone concentrations were affected to a higher degree than oxycodone (see section 5.2). The clinical relevance of a relative high naloxone exposure in hepatic impaired patients is yet not known. Caution must be exercised when administering Myloxifin to patients with mild hepatic impairment (see section 4.4). In patients with moderate and severe hepatic impairment Myloxifin is contraindicated (see section 4.3).
Patients with impaired renal function
A clinical trial has shown that plasma concentrations of both oxycodone and naloxone are elevated in patients with renal impairment (see section 5.2). Naloxone concentrations were affected to a higher degree than oxycodone. The clinical relevance of a relative high naloxone exposure in renal impaired patients is yet not known. Caution should be exercised when administering Myloxifin to patients with renal impairment (see section 4.4).
Method of administration
For oral use.
These prolonged-release tablets are taken in the determined dose twice daily in a fixed time schedule.
The prolonged-release tablets may be taken with or without food with sufficient liquid.
Myloxifin 10 mg / 5 mg
The tablet can be divided into equal doses. Myloxifin must be swallowed with sufficient liquid, and must not be broken, chewed or crushed
Duration of use
Myloxifin should not be administered for longer than absolutely necessary. If long-term treatment is necessary in view of the nature and severity of the illness, careful and regular monitoring is required to establish whether and to what extent further treatment is necessary.
Analgesia
When the patient no longer requires opioid therapy, it may be advisable to taper the dose gradually (see section 4.4).
If the patient does not require opioid treatment anymore, it is advisable to withdraw the medicinal product gradually, over about a week, in order to reduce the risk of a withdrawal reaction (see section 4.4).
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1,
• severe respiratory depression with hypoxia and/or hypercapnia,
• severe chronic obstructive pulmonary disease,
• Cor pulmonale,
• severe bronchial asthma,
• non-opioid induced paralytic ileus,
• moderate to severe hepatic impairment.
Respiratory depression
The major risk of opioid excess is respiratory depression. Caution must be exercised when administering Myloxifin to elderly or infirm patients, patients with opioid-induced paralytic ileus, patients presenting severely impaired pulmonary function, patients with sleep apnoea, myxoedema, hypothyroidism, Addison's disease (adrenal cortical insufficiency), toxic psychosis, cholelithiasis, prostate hypertrophy, alcoholism, delirium tremens, pancreatitis, hypotension, hypertension, pre-existing cardiovascular diseases, head injury (due to the risk of increased intracranial pressure), epileptic disorder or predisposition to convulsions, or patients taking MAO inhibitors.
Hepatic or renal impairment
Caution must also be exercised when administering Myloxifin to patients with mild hepatic or renal impairment. A careful medical monitoring is particularly necessary for patients with severe renal impairment.
Hepatobiliary disorders
Oxycodone may cause dysfunction and spasm of the sphincter of Oddi, thus increasing the risk of biliary tract symptoms and pancreatitis. Therefore, oxycodone / naloxone has to be administered with caution in patients with pancreatitis and diseases of the biliary tract.
Diarrhoea
Diarrhoea may be considered as a possible effect of naloxone.
Drug dependence, tolerance and potential for abuse
Opioid Use Disorder (abuse and dependence)
Tolerance and physical and/or psychological dependence may develop upon repeated administration of opioids such as oxycodone. Iatrogenic addiction following therapeutic use of opioids is known to occur.
Repeated use of Myloxifin may lead to Opioid Use Disorder (OUD). Abuse or intentional misuse of Myloxifin may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.
Tolerance
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance.
The risks of developing tolerance should be explained to the patient.
Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction.
The clinical need for analgesic treatment should be reviewed regularly.
Drug withdrawal syndrome
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with oxycodone.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
Hyperalgesia
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain.
This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.
Long-term treatment
In patients under long-term opioid treatment with higher doses of opioids, the switch to Myloxifin can initially provoke withdrawal symptoms. Such patients may require specific attention.
Myloxifin is not suitable for the treatment of withdrawal symptoms.
Alcohol
Concomitant use of alcohol and Myloxifin may increase the undesirable effects of Myloxifin; concomitant use should be avoided.
Paediatric population
Studies have not been performed on the safety and efficacy of Myloxifin in children and adolescents below the age of 18 years. Therefore, their use in children and adolescents under 18 years of age is not recommended.
Cancer
There is no clinical experience in patients with cancer associated to peritoneal carcinomatosis or with sub-occlusive syndrome in advanced stages of digestive and pelvic cancers. Therefore, the use of Myloxifin in this population is not recommended.
Surgery
Myloxifin is not recommended for pre-operative use or within the first 12-24 hours post-operatively. Depending on the type and extent of surgery, the anaesthetic procedure selected, other co-medication and the individual condition of the patient, the exact timing for initiating post-operative treatment with Myloxifin depends on a careful risk-benefit assessment for each individual patient.
Abuse
Any abuse of Myloxifin by drug addicts is strongly discouraged.
If abused parenterally, intranasally or orally by individuals dependent on opioid agonists, such as heroin, morphine, or methadone, Myloxifin is expected to produce marked withdrawal symptoms - because of the opioid receptor antagonist characteristics of naloxone - or to intensify withdrawal symptoms already present (see section 4.9).
These tablets intended for oral use only. Abusive parenteral injections of the prolonged-release tablet constituents (especially talc) can be expected to result in local tissue necrosis and pulmonary granulomas or may lead to other serious, potentially fatal undesirable effects.
The empty prolonged‑release tablet matrix may be visible in the stool.
Doping
Athletes must be aware that this medicine may cause a positive reaction to 'anti-doping' tests. The use of Myloxifin as a doping agent may become a health hazard.
Substances having a CNS-depressant effect (e.g. other opioids, sedatives, hypnotics, antidepressants, phenothiazines, neuroleptics, antihistamines and antiemetics) may enhance the CNS-depressant effect (e.g. respiratory depression) of Myloxifin.
Concomitant administration of oxycodone with anticholinergics or medications with anticholinergic activity (e.g. tri-cyclic antidepressants, antihistamines, anti-psychotics, muscle relaxants, anti-Parkinson drugs) may result in increased anticholinergic adverse effects.
Alcohol may enhance the pharmacodynamic effects of Myloxifin; concomitant use should be avoided.
Clinically relevant changes in International Normalised Ratio (INR or Quick-value) in both directions have been observed in individuals if oxycodone and coumarin anticoagulants are co-applied.
Oxycodone is metabolised primarily via the CYP3A4 pathways and partly via the CYP2D6 pathway (see section 5.2). The activities of these metabolic pathways may be inhibited or induced by various co-administered drugs or dietary elements. Myloxifin doses may need to be adjusted accordingly.
CYP3A4 inhibitors, such as macrolide antibiotics (e.g. clarithromycin, erythromycin, telithromycin), azole-antifungal agents (e.g. ketoconazole, voriconazole, itraconazole, posaconazole), protease inhibitors (e.g. ritonavir, indinavir, nelfinavir, saquinavir), cimetidine and grapefruit juice may cause decreased clearance of oxycodone which could lead to an increase in oxycodone plasma concentrations. A reduction in the dose of Myloxifin and subsequent re-titration may be necessary.
CYP3A4 inducers, such as rifampicin, carbamazepine, phenytoin and St. John's Wort, may induce the metabolism of oxycodone and cause increased clearance of the drug, resulting in a decrease in oxycodone plasma concentrations. Caution is advised and further titration may be necessary to reach an adequate level of symptom control.
Theoretically, medicinal products that inhibit CYP2D6 activity, such as paroxetine, fluoxetine and quinidine, may cause decreased clearance of oxycodone which could lead to an increase in oxycodone plasma concentrations. Concomitant administration with CYP2D6 inhibitors had an insignificant effect on the elimination of oxycodone and also had no influence on the pharmacodynamic effects of oxycodone.
In vitro metabolism studies indicate that no clinically relevant interactions are to be expected between oxycodone and naloxone. The likelihood of clinically relevant interactions between paracetamol, acetylsalicylic acid or naltrexone and the combination of oxycodone and naloxone in therapeutic concentrations is minimal.
Pregnancy
Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.
If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.
There are no data from the use of Myloxifin in pregnant women and during childbirth. Limited data on the use of oxycodone during pregnancy in humans reveal no evidence of an increased risk of congenital abnormalities. For naloxone, insufficient clinical data on exposed pregnancies are available. However, systemic exposure of the women to naloxone after use of Myloxifin is relatively low (see section 5.2).
Both oxycodone and naloxone pass into the placenta. Animal studies have not been performed with oxycodone and naloxone in combination (see section 5.3). Animal studies with oxycodone or naloxone administered as single drugs have not revealed any teratogenic or embryotoxic effects.
Myloxifin should only be used during pregnancy if the benefit outweighs the possible risks to the unborn child or neonate.
Breastfeeding
Administration to nursing women is not recommended as oxycodone may be secreted in breast milk and may cause respiratory depression in the infant.
A milk-plasma concentration ratio of 3.4:1 was measured and oxycodone effects in the suckling infant are therefore conceivable. It is not known whether naloxone also passes into the breast milk. However, after use of oxycodone/naloxone systemic naloxone levels are very low (see section 5.2).
A risk to the suckling child cannot be excluded in particular following intake of multiple doses of Myloxifin by the breastfeeding mother.
Breastfeeding should be discontinued during treatment with Myloxifin.
Fertility
There are no data with respect to fertility.
Myloxifin has moderate influence on the ability to drive and use machines. This is particularly likely at the beginning of treatment with Myloxifin, after dose increase or product rotation and if Myloxifin is combined with other CNS depressant agents. Patients stabilised on a specific dose will not necessarily be restricted. Therefore, patients should consult with their physician as to whether driving or the use of machinery is permitted.
Patients being treated with Myloxifin and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see sections 4.5 and 4.7).
Undesirable effects are presented below in three sections: the treatment of pain, the active substance oxycodone hydrochloride.
The following frequencies are the basis for assessing undesirable effects:
Very common
Common
Uncommon
Rare
Very rare
Not known
≥1/10
≥1/100 to <1/10
≥1/1,000 to <1/100
≥1/10,000 to <1/1,000
<1/10,000
cannot be estimated from the available data
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Undesirable effects for treatment of pain
System organ class
MedDRA
Common
Uncommon
Rare
Very rare
Not known
Immune system disorders
Hyper-sensitivity
Metabolism and nutrition disorders
Decreased appetite up to loss of appetite
Psychiatric disorders
Insomnia
Restlessness, Abnormal thinking, Anxiety, Confusion state, Depression, libido decreased, Nervousness
Euphoric mood, Hallucination, Nightmares, Drug dependence (see section 4.4.)
Nervous system disorders
Dizziness, Headache, Somnolence,
Convulsions1
Disturbance in attention
dysgeusia
Speech disorder
Syncope
Tremor
lethargy
Paraesthesia, Sedation
Eye disorders
Visual impairment
Ear and labyrinth disorders
Vertigo
Cardiac disorders
Angina pectoris2, Palpitations
Tachycardia
Vascular disorders
Hot flush
Decrease in blood pressure, Increase in blood pressure
Respiratory, thoracic and mediastinal disorders
Dyspnoea, Rhinorrhoea, Cough
Yawning
Respiratory depression
Gastrointestinal disorders
Abdominal pain, Constipation, Diarrhoea, Dry mouth, Dyspepsia, Vomiting, Nausea, Flatulence
Abdominal distention
Tooth disorder
Eructation
Hepatobiliary disorders
Hepatic enzymes increased, Biliary colic
Sphincter of Oddi dysfunction
Skin and subcutaneous tissue disorders
Pruritus, Skin reactions, Hyperhidrosis
Musculo-skeletal and connective tissue disorders
Muscle spasms, Muscle twitching, Myalgia
Renal and urinary disorders
Micturition urgency
Urinary retention
Reproductive system and breast disorders
Erectile dysfunction
General disorders and administration site conditions
Asthenic, fatigue
Drug withdrawal syndrome, Chest pain, Chills, Malaise, Pain, Peripheral, oedema, thirst
Investigations
Weight decreased
Weight increased
Injury, poisoning and procedural complications
Injury from accidents
1 particularly in persons with epileptic disorder or predisposition to convulsions
2 particular in patients with history of coronary artery disease
For the active substance oxycodone hydrochloride, the following additional undesirable effects are known
Due to its pharmacological properties, oxycodone hydrochloride may cause respiratory depression, miosis, bronchial spasm and spasms of nonstriated muscles as well as suppress the cough reflex.
System organ class
MedDRA
Common
Uncommon
Rare
Very rare
Not known
Infections and infestations
Herpes simplex
Immune system disorders
Anaphylactic reactions
Metabolism and nutrition disorders
Dehydration
Increased appetite
Psychiatric disorders
Altered mood and personality changes
Decreased activity
Psychomotor hyperactivity
Agitation, Perception disturbances (e.g. derealisation), Drug dependence
Aggression
Nervous system disorders
Concentration impaired, Migraine, Hypertonia , Involuntary muscle contractions, Hypoaesthesia, Abnormal co-ordination
Hyperalgesia
Ear and labyrinth disorders
Hearing impaired
Vascular disorders
Vasodilation
Respiratory, thoracic and mediastinal disorders
Dysphonia
Gastrointestinal disorders
Hiccups
Dysphagia, Ileus, Mouth ulceration, Stomatitis
Melaena, Gingival bleeding
Dental caries
Hepatobiliary disorders
Cholestasis
Skin and subcutaneous tissue disorders
Dry skin
Urticaria
Renal and urinary disorders
Dysuria
Reproductive system and breast disorders
Hypogonadism
Amenorrhoe
General disorders and administration site conditions
Oedema, Drug tolerance
Drug withdrawal syndrome neonatal
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the MHRA Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
Symptoms of intoxication
Depending on the history of the patient, an overdose of Oxycodone/Naloxone Myloxifin may be manifested by symptoms that are either triggered by oxycodone (opioid receptor agonist) or by naloxone (opioid receptor antagonist).
Symptoms of oxycodone overdose include miosis, respiratory depression, somnolence progressing to stupor, hypotonia, bradycardia as well as hypotension. Coma, non-cardiogenic pulmonary oedema and circulatory failure may occur in more severe cases and may lead to a fatal outcome.
Symptoms of a naloxone overdose alone are unlikely.
Therapy of intoxication
Withdrawal symptoms due to an overdose of naloxone should be treated symptomatically in a closely-supervised environment.
Clinical symptoms suggestive of an oxycodone overdose may be treated by the administration of opioid antagonists (e.g. naloxone hydrochloride 0.4-2 mg intravenously). Administration should be repeated at 2-3 minute intervals, as clinically necessary. It is also possible to apply an infusion of 2 mg naloxone hydrochloride in 500 ml of 0.9% sodium chloride or 5% dextrose (0.004 mg/ml naloxone). The infusion should be run at a rate aligned to the previously administered bolus doses and to the patient's response.
Consideration may be given to gastric lavage.
Supportive measure (artificial ventilation, oxygen, vasopressors and fluid infusions) should be employed as necessary, to manage the circulatory shock accompanying an overdose. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation. Artificial ventilation should be applied if necessary. Fluid and electrolyte metabolism should be maintained.
Ask anything about Myloxifin 10 mg/5 mg prolonged-release tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.